Fact CheckerSign in

NCT05111288Recruiting

Influence of Pulse Electromagnetic Field Therapy on Myocardial Ischemia

Source: ClinicalTrials.gov · Last updated 9 Sept 2026

Brief summary (registry, in English)

This study is being done to observe the effects of treatment from a device called the Bioboosti which utilizes pulsed electromagnetic waves on its ability to improve blood flow to the heart tissue in individuals with coronary artery disease (CAD).

Status (registry)
Recruiting
Study type
Interventional
Enrollment
120 (estimated)
First submitted
27 Oct 2021
Start date
18 May 2022
Primary completion date
Jun 2027
Lead sponsor
Mayo Clinic
NCT number
NCT05111288

What you commit to

  • Study type: Interventional
  • Planned participants: 120
  • From 18 May 2022 to the primary completion date, Jun 2027
  • 2 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Severe lung disease.
  • Significant arrhythmia (ventricular tachycardia, ventricular fibrillation, frequent premature ventricular contractions (PVCs), persistent atrial fibrillation, or 2nd or 3rd degree atrioventricular (AV) block).
  • Seizures.
  • Unstable angina.
  • Recent myocardial infarction (\< 90 days).

Lab values

  • Anemia (\< 7 mg/dl).
  • Low potassium (\< 3 mmol/L).
  • Creatinine (\> 5.0 mg/dl or \< 0.6 mg/dl).

Other

  • Unable to exercise due primarily to orthopedic limitation.
  • Morbid obesity (BMI \> 42).
  • Pregnant.
  • Breast feeding.
  • Coronary spasm.
  • Recent percutaneous coronary intervention (\<90 days).

Who the study is looking for

  • Age ≥ 18 years old.
  • Known cardiac ischemia, who are non revascularizable, or have not and will not be undergo coronary intervention for the duration of their participation in the study.
  • Evidence of ischemia from previous clinical tests (echo, nuclear, standard ECG from past 6 months).
  • Left Ventricular Ejection fraction \> 40% by echo (evaluated last 3 months).
  • Able to complete a cardiopulmonary exercise test without significant non cardiac limitations, primarily orthopedic.
  • On guideline directed optimal therapy for stable ischemia.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Mayo Clinic in Rochester
Coordinator of this site? Confirm its status
RochesterUnited StatesRecruiting
Mayo Clinic in Arizona
Coordinator of this site? Confirm its status
ScottsdaleUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.